The UK Biobank data exposure highlights a growing risk in modern health research: sensitive data is not only vulnerable to breaches, but to systemic leakage through normal scientific practices. This raises urgent...read more
Category - Clinical genetics
Tempus Scoops Up OneOme’s Pharmacogenetics Assets as Precision Medicine Shakeout Continues
Tempus AI has acquired the pharmacogenetics assets of OneOme, a once-promising precision medicine startup that abruptly shut down earlier this year amid financial troubles. The deal marks the latest in a flurry of...read more
Abbott to acquire Exact Sciences
• Acquisition adds a new growth vertical to Abbott’s already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments•...read more
Tempus Announces the Acquisition of Paige
Paige’s strong foundation in pathology and AI is rooted in its proprietary dataset of almost 7 million digitized pathology slides that are clinically annotated Tempus AI, Inc. (NASDAQ: TEM), a technology company leading...read more
